Detalhes bibliográficos
| Ano de defesa: |
2024 |
| Autor(a) principal: |
Bonafé, Diana Holkem |
| Orientador(a): |
Gomes , Patricia |
| Banca de defesa: |
Figueiredo , José Antonio Poli de,
Mortari, Sérgio Roberto |
| Tipo de documento: |
Dissertação
|
| Tipo de acesso: |
Acesso aberto |
| Idioma: |
por |
| Instituição de defesa: |
Universidade Franciscana
|
| Programa de Pós-Graduação: |
Programa de Pós-Graduação em Nanociências
|
| Departamento: |
Biociências e Nanomateriais
|
| País: |
Brasil
|
| Palavras-chave em Português: |
|
| Palavras-chave em Inglês: |
|
| Área do conhecimento CNPq: |
|
| Link de acesso: |
http://www.tede.universidadefranciscana.edu.br:8080/handle/UFN-BDTD/1312
|
Resumo: |
Squamous cell carcinoma (SCC), also known as squamous cell carcinoma, is a genetic mutation that occurs during cell duplication. This subtype of cancer originates in the oral mucosa, pharynx, and/or larynx, and is characterized by a high rate of oral malignant neoplasms and high mortality. Current treatments are aggressive and cause numerous side effects, such as xerostomia, mucositis, and osteoradionecrosis. Therefore, alternatives are being studied to treat carcinomas, including the use of natural compounds. Cocoa and grape have been tested as alternative treatments for SCC due to their phenolic compounds. Nanotechnology contributes to this study by improving the stability and protection of bioactives, as well as contributing to the circular bioeconomy. The objective of this work was to develop and produce nanoparticles containing cocoa by-products and grape seed, evaluating their safety profile and anticancer efficacy in vitro. The justification is to develop a natural product with antitumor effects, acting as an adjuvant treatment to current methods. Initially, the pre-formulation of nanostructured lipid carriers containing cocoa butter (CB) and grape seed oil (GSO), designated CLN CB/GSO, was performed. The MODDE Pro® program was used for screening, optimization, and robustness verification, considering factors (independent variables) such as the percentage of CB, GSO, surfactants, and high-speed homogenization time, and responses (dependent variables) such as particle diameter, polydispersity index (PDI), zeta potential (ZP), ferric reducing antioxidant power (FRAP), and total antioxidant capacity (TAC). Measurements of particle diameter, PDI, and ZP were performed using the Zetasizer® Nano-ZS (Malvern), while FRAP and TAC were measured with the BS 380® (Mindray, Shenzhen, China). The robustness point (R) defined by the software was 2.766% (w/v) CB, 1.766% (w/v) GSO, 1.952% (w/v) Span 80®, and 1.952% (w/v) Tween 80®, with 50 minutes of Ultra Turrax time, presenting a failure probability of 24%. After the production of the carriers, the stability of the ideal formulation was evaluated, along with the safety profile in VERO cells and efficacy in SCC25 cells. The nanocarrier demonstrated stability in relation to PDI and particle diameter over 30 days, with a slight reduction in pH and PZ. Regarding the safety and efficacy profile, tests were performed at concentrations of 10, 25, 50, 100, 150, 200, and 1000 µg.mL-1 . Thus, the nanocarrier proved to be safe, generating a reduction of ROS and showing anticancer potential at most concentrations tested in 24 and 72 hours, especially at a concentration of 100 µg.mL-1. |
